A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy
Study of patients with neuropathy using study drug, ISIS TTR Rx
Sponsor: Isis Pharmaceuticals
Enrolling: Male and Female Patients
Study Length: 24 Months
Clinic Visits: 24
IRB Number: AAAK9563
Contact: Jacqueline Scoon: 212 305 6035 / js4462@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the efficacy and safety of ISIS TTR Rx given for 65 weeks in patients with Familial Amyloid Polyneuropathy (FAP). The purpose of this study is to determine if ISIS 420915 can help people with mild or moderate FAP. To be in this study you must have FAP and be able to walk without help or walk with using only one cane.
This study is closed
Investigator
Thomas Brannagan, MD
Do You Qualify?
Do you have kidney problems? Yes No
Have you had a liver transplant or anticipate receiving a liver transplant within the next year? Yes No
Are you able to walk unaided or with the use of only a cane? Yes No
Would you be willing to take Vitamin A supplements? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jacqueline Scoon
js4462@cumc.columbia.edu
212 305 6035
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE